The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | CLL: IgHV mutational status
Nicolas Martinez-Calle, MD, Nottingham University Hospitals NHS Trust, Nottingham, UK, outlines what he believes to be the most influential findings in chronic lymphocytic leukemia (CLL) research, specifically mentioning the use of IgHV mutational status in the personalization of CLL therapy This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
